Dose Range Finding Study of Fedovapagon in Men With Nocturia

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vantia Ltd
ClinicalTrials.gov Identifier:
NCT01656239
First received: July 31, 2012
Last updated: October 15, 2013
Last verified: October 2013

July 31, 2012
October 15, 2013
August 2012
August 2013   (final data collection date for primary outcome measure)
Change in the mean nocturnal urine voids [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01656239 on ClinicalTrials.gov Archive Site
  • Change in the mean nocturnal urine voids [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Change in the mean time to first nocturnal void [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Change in the mean time to first nocturnal void [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change in Nocturia-related quality of life (N-QOL) [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
  • Change in Nocturia-related quality of life (N-QOL) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Dose Range Finding Study of Fedovapagon in Men With Nocturia
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia

The purpose of this study is to determine the dose level(s) of fedovapagon which result in a decrease in the mean nocturnal void frequency.

Fedovapagon is a selective vasopressin V2 receptor (V2 receptor) agonist that is being developed for the treatment of Nocturia.

The antidiuretic effect of V2 receptor stimulation in the kidneys is well established through the use of the peptide agonist, desmopressin, which shows clinical benefit in diabetes insipidus, primary nocturnal enuresis and Nocturia.

Nocturia, defined as the complaint that the individual has to wake at night one or more times to void, is a common complaint and shows an age-dependent increase in both prevalence and severity (number of Nocturnal Voids). It is the most bothersome symptom of benign prostatic hypertrophy (BPH) and has been linked to an age-dependent loss in circadian release of endogenous nocturnal vasopressin and consequent over production of urine at night (Nocturnal Polyuria).

The purpose of this Phase IIb study is to determine the efficacy of different doses of fedovapagon in reducing the number of times subjects with Nocturia void during the night together with other parameters including increasing the time between going to bed and waking to first void. By establishing the effective doses of fedovapagon on these clinical endpoints, the data from this study will determine the most appropriate dose(s) of fedovapagon for the treatment of Nocturia to be taken forward into further studies.

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Nocturia
  • Drug: fedovapagon 1 mg
  • Drug: fedovapagon 2 mg
  • Drug: fedovapagon 4 mg
  • Drug: Placebo ( sugar pill)
  • Experimental: fedovapagon 1 mg
    Once daily oral dose of 1 mg fedovapagon for 12 weeks
    Intervention: Drug: fedovapagon 1 mg
  • Experimental: fedovapagon 2 mg
    Once daily oral dose of 2 mg fedovapagon for 12 weeks
    Intervention: Drug: fedovapagon 2 mg
  • Experimental: fedovapagon 4 mg
    Once daily oral dose of 4 mg fedovapagon for 12 weeks
    Intervention: Drug: fedovapagon 4 mg
  • Placebo Comparator: sugar pill
    Once daily oral dose of placebo for 12 weeks
    Intervention: Drug: Placebo ( sugar pill)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
358
September 2013
August 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males aged 55 or over
  • History and/ or symptoms of Nocturia (2 - 5 voids per night)
  • Generally well (concomitant illness / conditions well controlled)
  • Serum sodium, potassium, chloride and bicarbonate within normal limits
  • No clinically significant abnormalities in other laboratory parameters, urinalysis, electrocardiogram (ECG) or physical examination
  • Prostate specific antigen (PSA) within the normal range or not considered clinically significant
  • Ability to comply with the requirements of the study
  • Written informed consent.

Exclusion Criteria:

-

Male
55 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01656239
483-009
No
Vantia Ltd
Vantia Ltd
Not Provided
Study Director: Hilary McElwaine-Johnn, BSc, ASM, MBBS, MRCP, MFPM Vantia Ltd
Vantia Ltd
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP